EGFR and susceptibility to pneumonia measurement: pointed out that in patients with stage IV NSCLC undergoing EGFR-TKI and stereotactic radiotherapy, only 6.67% developed grade 2 pneumonia, with no observations of grade 3 or higher levels of pulmonary toxicity (41).